Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals PIC

Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103

Fineline Cube Aug 31, 2026
Company Deals PIC

Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline

Fineline Cube Aug 31, 2026
Company Drug PIC

Eli Lilly Wins FDA Approval for Mounjaro Cardiovascular Risk Reduction in Type 2 Diabetes

Fineline Cube Aug 31, 2026
Company Drug PIC

Takeda Wins FDA Approval for MIMRYLO, First‑in‑Class Hepcidin Mimetic for Polycythemia Vera

Fineline Cube Aug 31, 2026
Company Deals PIC

AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline

Fineline Cube Aug 28, 2026
Company Deals PIC

Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103

Fineline Cube Aug 31, 2026
Policy / Regulatory

GluBio’s GLB‑005 WIZ Degrader Enters NMPA Rare Disease Pilot for β‑Thalassemia

Fineline Cube Aug 31, 2026
Company Deals PIC

Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103

Fineline Cube Aug 31, 2026
Company Medical Device

Peijia Medical’s YonFlow Stent Approved by China’s NMPA

Fineline Cube Apr 10, 2025

Peijia Medical Ltd (HKG: 9996) announced that it has received market approval from China’s National...

Company Medical Device

Gaush Meditech’s Corneal Confocal Microscope Approved in Jiangsu

Fineline Cube Apr 10, 2025

Suzhou-based Gaush Meditech Ltd (HKG: 2407) announced that it has received market approval from the...

Company Drug

Simcere Pharmaceutical Gains NMPA Approval for FGFR2b-Targeted ADC SIM0686

Fineline Cube Apr 10, 2025

China-based Simcere Pharmaceutical Group (HKG: 2096) announced that it has received clearance from the National...

Company Deals

Sinopep-Allsino Partners with Gulf Pharmaceutical for Semaglutide API Supply

Fineline Cube Apr 10, 2025

Jiangsu-based Contract Development and Manufacturing Organization (CDMO) Sinopep-Allsino Biopharmaceutical Co., Ltd (SHA: 688076) has signed...

Policy / Regulatory

U.S. Tariffs on Pharmaceuticals and Their Impact on China’s Medical Industry

Fineline Cube Apr 9, 2025

The U.S. administration’s decision to impose tariffs on pharmaceutical imports, effective April 9, has sent...

Company Drug

Sichuan Biokin Launches Phase III Trial for BL-B01D1 in Urothelial Carcinoma

Fineline Cube Apr 9, 2025

China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced the first patient enrollment in...

Company Drug

AbbVie’s Rinvoq Approved in EU for Giant Cell Arteritis

Fineline Cube Apr 9, 2025

US-based pharmaceutical giant AbbVie (NYSE: ABBV) announced that it has received marketing approval in the...

Company Drug

Bristol-Myers Squibb’s Opdivo/Yervoy Combo Approved for MSI-H Colorectal Cancer

Fineline Cube Apr 9, 2025

Bristol-Myers Squibb (BMS, NYSE: BMY) announced this week that the US Food and Drug Administration...

Company Drug

Yifan Pharma Secures NMPA Approval for Generic Sedapain

Fineline Cube Apr 9, 2025

China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) has announced that it has received marketing approval...

Company Drug

Yunnan Baiyao’s INR102 Gains NMPA Clinical Trial Clearance for Prostate Cancer

Fineline Cube Apr 9, 2025

Yunnan Baiyao Group Co., Ltd (SHE: 000538), a traditional Chinese medicine (TCM) company based in...

Company Deals

Shanghai Kehua Bioengineering Launches Xi’an Medical Complex Project

Fineline Cube Apr 9, 2025

Shanghai Kehua Bioengineering Co., Ltd (SHE: 002022), a leading Chinese biotechnology company, has announced plans...

Company Deals

HuidaGene’s hfCas12Max Licensed to Vita Therapeutics for Neuromuscular Cell Therapy

Fineline Cube Apr 9, 2025

Shanghai-based genome medicines specialist HuidaGene Therapeutics has sublicensed its hfCas12Max platform to Vita Therapeutics, Inc.,...

Policy / Regulatory

NMPA Optimizes Drug Manufacturing License Process with Digital QR Codes

Fineline Cube Apr 9, 2025

The National Medical Products Administration (NMPA) has announced new measures to optimize the drug manufacturing...

Company Drug

Bayer Submits Eylea 8 mg for RVO Macular Edema Approval in EU

Fineline Cube Apr 9, 2025

German pharmaceutical giant Bayer (ETR: BAYN) announced that it has submitted an indication approval filing...

Company Deals

Aidea Pharma Terminates COVID-19 Drug Collaboration with PharmaBlock

Fineline Cube Apr 9, 2025

China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) announced the termination of its development collaboration...

Company Drug

Daiichi Sankyo and AstraZeneca’s Datroway Approved in EU for Breast Cancer

Fineline Cube Apr 9, 2025

Japan-based Daiichi Sankyo (TYO: 4568) and UK major AstraZeneca (NASDAQ: AZN) announced that their co-developed...

Company Deals

IDT and Shanghai Bioscience Forge Partnership to Drive Local Innovation in China

Fineline Cube Apr 9, 2025

Integrated DNA Technologies (IDT), a leading life sciences and diagnostics company under the Danaher Corporation...

Company

Bio-Thera Solutions Reports 5.44% Revenue Growth in 2024 Driven by Biosimilar Sales

Fineline Cube Apr 9, 2025

Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced its 2024 financial results, recording RMB 743.17 million (USD...

Company Drug

Winsunny Pharma’s FY101 Gains NMPA Clinical Approval for Hyperlipidemia

Fineline Cube Apr 9, 2025

China-based Beijing Winsunny Pharmaceutical Co., Ltd (SHA: 601089) announced that it has received clinical approval...

Company Medical Device

HighLife SAS’s TMVR System Receives FDA Breakthrough Device Designation

Fineline Cube Apr 9, 2025

Medical device firm HighLife SAS, the French partner of China-based Peijia Medical Limited (HKG: 9996),...

Posts pagination

1 … 228 229 230 … 713

Recent updates

  • GluBio’s GLB‑005 WIZ Degrader Enters NMPA Rare Disease Pilot for β‑Thalassemia
  • Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103
  • Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline
  • Eli Lilly Wins FDA Approval for Mounjaro Cardiovascular Risk Reduction in Type 2 Diabetes
  • Takeda Wins FDA Approval for MIMRYLO, First‑in‑Class Hepcidin Mimetic for Polycythemia Vera
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

GluBio’s GLB‑005 WIZ Degrader Enters NMPA Rare Disease Pilot for β‑Thalassemia

Company Deals PIC

Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103

Company Deals PIC

Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline

Company Drug PIC

Eli Lilly Wins FDA Approval for Mounjaro Cardiovascular Risk Reduction in Type 2 Diabetes

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.